<DOC>
	<DOC>NCT01450605</DOC>
	<brief_summary>The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Reyataz® so that the regulatory authority can manage the marketing approval properly</brief_summary>
	<brief_title>Korean Post-marketing Surveillance for Reyataz®</brief_title>
	<detailed_description />
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Patients ≥ 13 years of age with HIV1 who are on Reyataz® treatment at the time of enrollment and have never been participated in this study previously or who are initiating Reyataz® treatment for the first time in the reallife conditions in its registered indication(s) as required by KFDA According to Warning/Caution in local label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>